Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Osteoarthritis Label Should Reflect Clinical Data For Broader Claims- PhRMA

Executive Summary

Osteoarthritis drug labeling should reflect results of specific clinical trials instead of a predetermined pain/function claim structure so that drugs obtain the broadest possible claim, the Pharmaceutical Research & Manufacturers of America suggested in April 20 comments on FDA's draft guidance on "Clinical Development Programs for Drugs, Devices and Biological Products Intended for the Treatment of Osteoarthritis."
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS032155

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel